Taysha Gene Therapies Inc Dossier
Qualitative Analysis
Business overview
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS). The company's lead clinical program is TSHA-102, an investigational gene transfer therapy in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause. TSHA-102 is a self-complementary, intrathecally delivered AAV9 therapy designed to deliver a functional MECP2 gene. Taysha operates as a single business segment focused on the development of these gene therapies.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing resources on advancing TSHA-102 in clinical trials (REVEAL and ASPIRE) for Rett syndrome.
Expected impact: Establish a streamlined path to a BLA submission and secure a broad label for patients aged two and older.
Preparing the commercial manufacturing infrastructure and building commercial inventory for TSHA-102.
Expected impact: Ensure adequate product supply to support a rapid and successful commercial launch upon potential regulatory approval.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Taysha with significant capital, global development expertise, and validation of its gene therapy platform [2.3.1].
Terms: Astellas made a $50 million strategic investment for a 15% stake and secured options to license TSHA-102 and TSHA-120.
Supports preclinical research and development programs, providing access to cutting-edge scientific research.